Pine Brook-based Frier Levitt, a national law firm specializing in health care and life sciences, on Monday announced the addition of Edgar Asebey and Guilherme Ferrari Faviero to its team. The new attorneys will significantly enhance the firm’s capabilities in FDA regulatory, cannabis, and broader life sciences law, serving a diverse range of clients from innovative startups to established global corporations.
Asebey brings over two decades of experience in FDA regulatory and transactional law. A former scientist and biotech founder, Asebey has a unique background that combines legal and scientific expertise. He previously served as an equity partner at a major national law firm and as an advisor for a venture capital fund. His work spans key sectors, including pharmaceuticals, biotechnology, food, dietary supplements, and emerging markets like cannabis, hemp, and psychedelics.
Daniel Frier, the firm’s co-managing partner, highlighted the value of Asebey’s dual expertise. “Edgar’s background as both a lawyer and scientist uniquely positions him to advise FDA-regulated companies navigating today’s complex regulatory landscape,” Frier said. “His addition deepens our ability to serve clients in highly regulated and innovative sectors.”
Joining Asebey is Guilherme Ferrari Faviero, a scientist and regulatory expert with extensive experience advising life sciences companies on compliance, clinical research, and strategic regulatory matters. Both Asebey and Faviero are co-authors of “Legal Guide to the Business of Marijuana: Cannabis, Hemp and CBD Regulation,” a leading publication on the legal framework for emerging cannabis and hemp markets.
Asebey stated that Frier Levitt provides an “ideal platform” to continue offering specialized legal and transactional support. He expressed excitement about collaborating with colleagues to deliver solutions that integrate legal strategy, scientific expertise, and regulatory knowledge.
The new hires underscore Frier Levitt’s commitment to thought leadership and expanding its national presence in the life sciences and health care sectors.
